Navigation Links
Orchid Cellmark Reports Third Quarter 2008 Financial Results
Date:11/18/2008

anagement capabilities in the U.K. will influence revenue and gross margin in the fourth quarter. However, we believe the fundamentals of our core business are sound; we have achieved efficiencies in our operations; and we have a strong balance sheet with $15.9 million in cash at the end of the quarter. The DNA identity testing market offers growth opportunities with market dynamics favorable in the U.S. and a changing market in the U.K. that affords us good prospects for gaining market share."

Conference Call Information

A conference call with Orchid Cellmark management will be held on Thursday, October 30, 2008 at 10:00 a.m. EDT. To listen to the conference call, please dial (877) 266-0703 or (706) 643-7682 and ask for the Orchid Cellmark conference call, conference number 70588526. To listen to the live or archived webcast via the Internet, please visit the Investors section of the company's web site at www.orchidcellmark.com. The webcast will be available for replay for 90 days after the conference call.

About Orchid Cellmark

Orchid Cellmark (Nasdaq: ORCH) is a leading international provider of DNA testing services primarily for forensic and family relationship applications. Orchid Cellmark is one of the largest providers of forensic DNA testing services and its DNA results are used by the criminal justice system to assist with the identification of perpetrators, the exclusion of suspects and the exoneration of wrongfully convicted individuals. The company provides DNA family relationship testing to numerous child services organizations and individuals seeking to verify parentage. Orchid Cellmark also serves immigration and security authorities for DNA testing of individuals. In the agriculture field, the company provides DNA t
'/>"/>

SOURCE Orchid Cellmark Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Saving the wild orchids of Borneo
2. Orchid Cellmark to Present at the 2008 Bank of America Health Care Conference
3. First orchid fossil puts showy blooms at some 80 million years old
4. Communication Intelligence Corporation Reports Third Quarter 2008 Financial Results
5. Synaptics Reports Record Results for First Quarter of Fiscal 2009
6. GEN reports on novel tools for deciphering biological networks
7. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
8. LSUHSC research reports new method to protect brain cells from diseases like Alzheimers
9. Communication Intelligence Corporation Reports Second Quarter 2008 Financial Results
10. BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008
11. BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... Stents that keep weakened and flabby arteries fr...r six months, those stents are no longer needed --...nnecessary. Previously, doctors had no choice but ... of Tel Aviv University,s Department of Biomedical...ber platform that carries drugs where they,re need...
(Date:11/24/2009)... Springer and the American College of Medical Tox...rate on the publication of the Journal of Medical...MT, beginning in March 2010. It was previously pu..., The Journal of Medical Toxicology , an intern...vancing the science and practice of medical toxico...
(Date:11/24/2009)..., BATON ROUGE Antarctica has long held secrets ...nd until recently, there has been very little info...beneath miles of ice for millions of years. Now, a...ding LSU have been funded to the tune of $10 mill... NSF, to get to the bottom of things literally. T...
Breaking Biology News(10 mins):A coating for life 2Springer and the American College of Medical Toxicology to work together 2LSU gets to the bottom of things -- in Antarctica 2Endologix Announces Live Web Cast of Presentation in SMH Capital Small Cap Spotlight on June 17 2009 at 4 3A15 p m ET 48957 1Endologix Announces Live Web Cast of Presentation in SMH Capital Small Cap Spotlight on June 17 2009 at 4 3A15 p m ET 48957 2Psoriasis Raises Risk of Heart Attack Stroke Death 48954 1Psoriasis Raises Risk of Heart Attack Stroke Death 48954 2MUHC researcher awarded 24500 000 to study pathogenesis of infectious disease 48951 1MUHC researcher awarded 24500 000 to study pathogenesis of infectious disease 48951 2
... that moonlight, having different roles at differe... being killed. The moonlighting activity of one en...ially resistant to a family of broad-spectrum anti...tember issue of the journal Microbiology. , "G...eria use to make the building blocks of cell walls...
...y recent reports documenting the therapeutic effic...odels of human disease may actually be describing ...ility of siRNA to activate an immune response, acc...ume 19, Number 9) of Human Gene Therapy , a peer-...c. The paper, which was published "instant online,...
...ncerned about the toll that mental health disorder...l have a unique opportunity to hear from world-cla...es, symptoms and progression of such illnesses as ...ia and autism, and learn about current and potenti... Healthy Minds Across America, 48 free public foru...
Other Biology News:Energy-saving bacteria resist antibiotics 2Previous claims of siRNA therapeutic effects called into question by report in human gene therapy 2Healthy Minds Across America features 48 public forums on mental health research, Sept. 14 2Healthy Minds Across America features 48 public forums on mental health research, Sept. 14 3
(Date:11/24/2009)...eenmetforpatientswithadvanced-stage,orrecurrentend...e-FirstCall/-AEternaZentarisInc.(NASDAQ: AEZS ;TSX...yfocusedonendocrinetherapyandoncology,todayannounc...tedcytotoxicpeptideconjugate,AEZS-108(formerlyAN-1...ncer.Inapersonalizedhealthcareapproach,thestudysel...
(Date:11/24/2009)...e-FirstCall/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),th...ouncedthatithassubmittedaMAAtotheEuropeanMedicines...acementtherapyindevelopment,forthetreatmentofType1...forvelaglucerasealfathathasbeensubmitted,withprevi...Basedonaglobalsupplyshortageofthecurrentlyapproved...
(Date:11/24/2009)...RNewswire-FirstCall/--GenomicHealth,Inc.(Nasdaq: G...xecutiveChairman,willpresentatthe21stAnnualPiperJa...cember1,2009at10:00a.m.ET. ,, Toaccessthelivean...ttheInvestorRelationssectionofGenomicHealth,swebsi...ecttothewebsiteatleast15minutespriortothebeginning...
(Date:11/24/2009)...onnects Customers with Partners Validated to Proce...Products , Ottawa, ON (PR... provider of products for biological sample collec...ed its new global partner program. The program off...tner community and is designed to help partners sc...
Breaking Biology Technology:AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Genomic Health to Present at Piper Jaffray Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...ented at the AACR,meeting in San Diego efficacy an... for ovarian cancer. FAS31 is an inhibitor of fatt...xpressed in many human cancers. Numerous,studies h...ytotoxic to a,variety of human xenograft models wi...AS31 showed no observable toxicity in normal tissu...
...asdaq:,EVVV) will release its 2008 first quarter f...gular market trading hours., The company will hos...30 a.m. CT (8:30 a.m. ET). ev3 management will rev... outlook, followed by a question and answer,sessio...rested parties through a,live audio webcast at ht...
...BCI), a,biopharmaceutical company utilizing its pl...s that promote the growth of new neurons for the t... announced today that it raised an,additional $20 ... bringing,the total to $50 million. New investor, ... investors and Alexandria Real Estate Equities, In...
Other Biology Technology:FASgen, Inc. Presents Ovarian Cancer Efficacy and Toxicology Data to the American Association for Cancer Research 2REVISED: BrainCells Inc. Expands Series B Financing to $50 Million 2
Mouse Anti-Human RDH5 Polyclonal Antibody, Unconjugated from Abnova Corporation
...Lines ,High Quality, Functionally-Validated, Ion C...or having a critical role in nerve and muscle func... CNS and the heart. Drugs that modulate ion channe...ch as neuropathic pain, cardiac arrhythmia, hypert...
The Discovery Series PDQuest Version Upgrade from Bio-Rad
Mouse Anti-Human ARHGEF11 Monoclonal Antibody, Unconjugated, Clone 2F4 from Abnova Corporation
Biology Products: